If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.
If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.
What can I do to prevent this in the future?
Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Chrome Web Store.
Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.
Cloudflare Ray ID: 674ddb767cb8376c • Your IP : 126.96.36.199 • Performance & security by Cloudflare
Request an accessible format.
This factsheet outlines the domestic control measures that apply to cannabis, cannabidiol (CBD) and controlled cannabinoids.
This file may not be suitable for users of assistive technology.
Drug licensing factsheet: cannabis, CBD and other cannabinoids
This factsheet is intended to be used by existing licensees and prospective licensees who may need to apply for a licence. They should have fully assessed any proposals they may wish to make in the context of this guidance and that provided by other regulators.
This is intended as general guidance only; it is not legal advice. Anyone in doubt should seek their own independent legal advice to ensure they are compliant with any relevant legislation.
This factsheet represents the Home Office’s view on the domestic control measures applicable to cannabis, cannabidiol (CBD) and controlled cannabinoids. It is intended as a resource for existing licensees and prospective licensees who may need to apply for a licence, having fully assessed any proposals they may wish to make in the context of this guidance and that provided by other regulators.
Where a preparation or product containing cannabis, cannabis resin, cannabinol or a cannabinol derivative does not meet the definition of a CBPM, it will be a Schedule 1 drug under the MDR 2001 unless the exempt product definition applies.
General legislative position and existing licensing arrangements
It is accepted that other countries may operate differing control regimes to the UK (which is outlined above). These alternative control regimes do not override UK domestic legislative requirements.
(c) is— (i) a medicinal product, or (ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product”
(b) is produced for medicinal use in humans; and—